Unifiram

guinea pig

Also seen as: DM-232, DM232, unifi

The Dose Guy’s verdict

Sep 1, 2026
2 sources

Unifiram is sunifiram’s rarer, less-studied cousin, and sunifiram already has zero human data. The animal pharmacology is clean: it reverses amnesia in mice at very low doses through an AMPA-dependent mechanism. That is the entire case. No human being has been studied on this compound, and the community that runs it is a fraction of the size of the sunifiram crowd. If you are drawn to the AMPA nootropic angle, sunifiram has more community mileage, and TAK-653 has actual human data, though TAK-653 is not broadly available either.

Would I take it?Caution, lab-rat territory.

What it is

A piperazine-derived research chemical from the same Italian university lab that produced sunifiram, sharing the same AMPA-receptor mechanism and even less data behind it. Unifiram boosts excitatory synaptic transmission in rat hippocampal slices, raises acetylcholine release from the cortex, and reverses drug-induced amnesia in mice at sub-milligram doses. One enantiomer is the active one, but nothing sold as unifiram specifies which you are getting.

It sits at the very tail of the nootropic shelf: a compound that exists because a lab synthesized it and vendors picked it up, not because anyone built a case for using it. TAK-653 is the AMPA modulator on this shelf with actual clinical data, if the mechanism is what draws you.

What the research shows

No human trials. Zero. Everything below is animal or in-vitro work. Read it as “interesting,” not “evidence it works in you.”

No human trial, no human pharmacokinetics, no human safety data. The literature is mouse behavior and rat tissue work from one research group.

Unifiram was active at 0.001 mg/kg subcutaneously in the mouse passive avoidance test.J Med Chem 2000 · mouse behavior

Unifiram at 0.1 mg/kg reversed NBQX-induced amnesia in mice, confirming AMPA receptor involvement. In rat hippocampal slices, it increased excitatory synaptic transmission.Naunyn-Schmiedeberg's 2003 · mouse and rat

No human clinical trial, pharmacokinetic study, or safety study of unifiram exists in PubMed.as of Aug 2026

Realistic protocols

I am not building a protocol table for a compound with no human data and barely any community track record. The small group that runs unifiram treats it like sunifiram: sublingual, 5 to 10 mg, on demand for acute focus. That is pattern-matching from the cousin, not evidence. If you run it, start at the low end, keep it occasional, do not combine it with other glutamatergic compounds, and log everything. Dose early, the activation is short but real enough to cost you sleep. Skip alcohol on dose days until you know how you respond. You are the study.

Side effects

Zero human safety data. What follows is inference from the mechanism and sparse forum reports:

anecdotalOverstimulation, headache, and a speedy feeling at higher doses. The unifiram community is too small to have much of its own report, so most of this is borrowed from the sunifiram crowd running the same mechanism.

unknownNo human has been studied on unifiram. No toxicology, no organ panel, no long-term data. The safety case is: mice tolerated it at effective doses. That is it.

Where to buy

No live listings from tracked vendors right now.